GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide inhibitor

Analyse Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6P8Z
Type
protein
Length
331 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
GDP, O5S, CA
Pockets
2 · best druggability 0.76

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AGTPase KRASprotein16538% helix, 25% strandP01116
BGTPase KRASprotein16639% helix, 25% strandP01116

Ligands and binding sites

  • GDP · Guanosine-5'-diphosphate · ligand · 2 copies · chains A, B
  • O5S · 2-[5-chloro-2-cyclopropyl-3-(5-methoxy-3,4-dihydroisoquinoline-2(1H)-carbonyl)-7-methyl-1H-indol-1-yl]-N-(1-propanoylazetidin-3-yl)acetamide · ligand · 2 copies · chains A, B
  • CA · Calcium ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15870.760.8268CA, GDP, O5S
22630.590.7841CA, GDP, O5S

Interfaces

1 interface between chains.

  • A–B · 572 Ų buried · 6 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 6P8Z · Crystal structure of human KRAS G12C covalently bound to an acryloylazetidine acetamide… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.